Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.